Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
EXTON, Pa., May 03, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2017 and recent operational highlights on Wednesday, May 10, 2017, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 888-539-3613 (domestic) or +1-719-457-2552 (international), and provide the conference code 9682774 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, has begun a Phase 1/2 trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow us on Twitter at @Fibrocell, and LinkedIn.
Investor & Media Relations Contact: Karen Casey 484-713-6133 [email protected]
